Elevance Health, Inc. $ELV is Immersion Capital LLP’s 5th Largest Position

Immersion Capital LLP raised its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 42.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 14,400 shares of the company’s stock after acquiring an additional 4,300 shares during the period. Elevance Health comprises about 7.3% of Immersion Capital LLP’s portfolio, making the stock its 5th biggest holding. Immersion Capital LLP’s holdings in Elevance Health were worth $5,048,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ELV. Rossby Financial LCC increased its holdings in Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after buying an additional 44 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of Elevance Health in the fourth quarter worth approximately $31,000. J.Safra Asset Management Corp bought a new position in shares of Elevance Health in the fourth quarter worth approximately $32,000. ORG Partners LLC boosted its position in shares of Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Elevance Health in the fourth quarter worth approximately $38,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the transaction, the director owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is owned by company insiders.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $392.04 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The firm has a fifty day moving average price of $372.34 and a 200 day moving average price of $346.21. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $426.98. The firm has a market cap of $85.13 billion, a price-to-earnings ratio of 16.68, a P/E/G ratio of 2.25 and a beta of 0.67.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the prior year, the business earned $11.97 earnings per share. Elevance Health’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts expect that Elevance Health, Inc. will post 26.93 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio is currently 29.26%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ELV shares. Leerink Partners set a $364.00 price target on shares of Elevance Health in a research report on Thursday, April 23rd. Mizuho upped their price target on shares of Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. UBS Group upped their price target on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Truist Financial upped their price target on shares of Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Finally, Guggenheim upped their price target on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $416.11.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.